

Francesco Bertoni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/305135/francesco-bertoni-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

362
papers

14,647
citations

63
h-index

111
g-index

404
ext. papers

17,014
ext. citations

5.4
avg, IF

6.13
L-index

#	Paper	IF	Citations
362	A novel phage display based platform for exosome diversity characterization.. <i>Nanoscale</i> , 2022 ,	7.7	5
361	Marginal-Zone Lymphomas.. <i>New England Journal of Medicine</i> , 2022 , 386, 568-581	59.2	7
360	KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells. <i>Oncology Reports</i> , 2022 , 47,	3.5	1
359	GPCR Inhibition in Treating Lymphoma. <i>ACS Medicinal Chemistry Letters</i> , 2022 , 13, 358-364	4.3	4
358	HMGA1 induces EZH2 overexpression in human B-cell lymphomas. <i>American Journal of Cancer Research</i> , 2021 , 11, 2174-2187	4.4	
357	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2021 ,	2.2	5
356	ASB2 is a direct target of FLI1 that sustains NF- κ B pathway activation in germinal center-derived diffuse large B-cell lymphoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 357	12.8	2
355	Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma. <i>Frontiers in Veterinary Science</i> , 2021 , 8, 647009	3.1	1
354	Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma. <i>Oncogene</i> , 2021 , 40, 3799-3814	9.2	5
353	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. <i>Blood Advances</i> , 2021 , 5, 2467-2480	7.8	3
352	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. <i>Nature Communications</i> , 2021 , 12, 734	17.4	10
351	Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity. <i>European Journal of Medicinal Chemistry Reports</i> , 2021 , 1, 100004		0
350	Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. <i>Trends in Cancer</i> , 2021 , 7, 823-836	12.5	3
349	The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021 , 2, 586-601	2.5	1
348	A New Network for the Advancement of Marine Biotechnology in Europe and Beyond. <i>Frontiers in Marine Science</i> , 2020 , 7,	4.5	7
347	Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog. <i>Veterinary and Comparative Oncology</i> , 2020 , 18, 645-655	2.5	3
346	Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	12

345	HMGA1-pseudogene7 transgenic mice develop B cell lymphomas. <i>Scientific Reports</i> , 2020 , 10, 7057	4.9	6
344	Biological and clinical implications of mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020 , 105, 448-456	6.6	35
343	An overview on anti-tubulin agents for the treatment of lymphoma patients. <i>Pharmacology & Therapeutics</i> , 2020 , 211, 107552	13.9	11
342	Understanding the mechanism of action of pyrrolo[3,2-]quinoxaline-derivatives as kinase inhibitors. <i>RSC Medicinal Chemistry</i> , 2020 , 11, 665-675	3.5	0
341	Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer. <i>American Journal of Cancer Research</i> , 2020 , 10, 572-580	4.4	5
340	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond. <i>Annals of Lymphoma</i> , 2020 , 4, 7	1.8	2
339	STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma. <i>Hematological Oncology</i> , 2020 , 38, 106-110	1.3	7
338	Pyrrolo[2,3-b,4]cyclohepta[1,2-][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 12023-12042	8.3	20
337	Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type. <i>Cancers</i> , 2020 , 12,	6.6	2
336	Targeting BET bromodomain proteins in cancer: The example of lymphomas. <i>Pharmacology & Therapeutics</i> , 2020 , 215, 107631	13.9	18
335	DNA Copy Number Changes in Diffuse Large B Cell Lymphomas. <i>Frontiers in Oncology</i> , 2020 , 10, 584095	5.3	4
334	Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. <i>Marine Drugs</i> , 2020 , 18,	6	28
333	Marginal Zone Lymphomas. <i>Cancer Journal (Sudbury, Mass)</i> , 2020 , 26, 336-347	2.2	3
332	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. <i>Blood Advances</i> , 2020 , 4, 4124-4135	5.8	13
331	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. <i>Blood Advances</i> , 2020 , 4, 819-829	7.8	16
330	Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences. <i>Cancer Treatment Reviews</i> , 2020 , 90, 102090	14.4	6
329	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. <i>Modern Pathology</i> , 2020 , 33, 179-187	9.8	11
328	mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020 , 105, 1604-1612	6.6	52

327	Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. <i>Haematologica</i> , 2020 , 105, 2584-2591	6.6	7
326	Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization. <i>Non-coding RNA</i> , 2019 , 5,	7.1	5
325	The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. <i>Haematologica</i> , 2019 , 104, e307-e309	6.6	11
324	Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3067-3076 ⁹	6.9	6
323	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. <i>Cancers</i> , 2019 , 11,	6.6	7
322	The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. <i>Clinical Cancer Research</i> , 2019 , 25, 5167-5176	12.9	21
321	DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1255-1264	6.1	13
320	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. <i>Haematologica</i> , 2019 , 104, e558-e561	6.6	31
319	Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq. <i>PLoS ONE</i> , 2019 , 14, e0215154	3.7	10
318	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019 , 33, 2416-2428	10.7	18
317	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. <i>Haematologica</i> , 2019 , 104, 1633-1639	6.6	13
316	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. <i>PLoS ONE</i> , 2019 , 14, e0212813	3.7	15
315	Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. <i>European Journal of Medicinal Chemistry</i> , 2019 , 181, 111545	6.8	7
314	Primary central nervous system lymphoma: Novel precision therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 141, 139-145	7	4
313	A Reliable Method to Remove Batch Effects Maintaining Group Differences in Lymphoma Methylation Case Study. <i>Lecture Notes in Computer Science</i> , 2019 , 24-32	0.9	
312	Single and combined BTK and PI3K inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. <i>British Journal of Haematology</i> , 2019 , 187, 595-601	4.5	8
311	Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. <i>Blood</i> , 2019 , 134, 2569-2569	2.2	1
310	The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines. <i>Blood</i> , 2019 , 134, 2574-2574	2.2	

309	Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 2858-2858	2.2	0
308	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019 , 133, 1664-1676	2.2	87
307	Genome-wide promoter methylation of hairy cell leukemia. <i>Blood Advances</i> , 2019 , 3, 384-396	7.8	10
306	The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines. <i>Frontiers in Oncology</i> , 2019 , 9, 1301	5.3	8
305	Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies. <i>Current Opinion in Hematology</i> , 2019 , 26, 273-280	3.3	3
304	In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas. <i>British Journal of Haematology</i> , 2019 , 186, 149-152	4.5	3
303	New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. <i>Haematologica</i> , 2019 , 104, e256-e259	6.6	23
302	The involvement of microRNA in the pathogenesis of Richter syndrome. <i>Haematologica</i> , 2019 , 104, 1004-1015	6.6	14
301	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. <i>Blood</i> , 2019 , 133, 156-167	2.2	27
300	Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019 , 184, 1022-1025	4.5	4
299	Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. <i>Haematologica</i> , 2018 , 103, e245-e248	6.6	18
298	Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides. <i>Journal of Biological Chemistry</i> , 2018 , 293, 5600-5612	5.4	34
297	Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. <i>Targeted Oncology</i> , 2018 , 13, 235-245	5	4
296	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , 2018 , 131, 2413-2425	2.2	122
295	BET Proteins as Targets for Anticancer Treatment. <i>Cancer Discovery</i> , 2018 , 8, 24-36	24.4	215
294	Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. <i>Nature Genetics</i> , 2018 , 50, 219-228	36.3	71
293	Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation. <i>British Journal of Haematology</i> , 2018 , 181, 129-133	4.5	10
292	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. <i>British Journal of Haematology</i> , 2018 , 182, 453-456	4.5	3

291	TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line. <i>British Journal of Haematology</i> , 2018 , 183, 509-512	4.5	5
290	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018 , 24, 120-129	12.9	54
289	IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. <i>Cancers</i> , 2018 , 10,	6.6	14
288	Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2018 , 103, 2049-2058	6.6	9
287	Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. <i>Hematological Oncology</i> , 2018 , 36, 757-764	1.3	3
286	Recent advances in understanding the biology of marginal zone lymphoma. <i>F1000Research</i> , 2018 , 7, 4063.6	2.5	25
285	Pixantrone: novel mode of action and clinical readouts. <i>Expert Review of Hematology</i> , 2018 , 11, 587-596	2.8	8
284	Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors. <i>Blood</i> , 2018 , 132, 4174-4174	2.2	1
283	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018 , 132, 922-922	2.2	2
282	First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS2619-TPS2619	2.2	4
281	cuRnet: an R package for graph traversing on GPU. <i>BMC Bioinformatics</i> , 2018 , 19, 356	3.6	2
280	Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach. <i>PLoS ONE</i> , 2018 , 13, e0208709	3.7	3
279	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. <i>ESMO Open</i> , 2018 , 3, e000387	6	14
278	T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways. <i>Frontiers in Oncology</i> , 2018 , 8, 317	5.3	18
277	restrains mast cell inflammatory responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E1490-E1499	11.5	68
276	Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. <i>Blood</i> , 2017 , 129, 2420-2428	2.2	30
275	PCSF: An R-package for network-based interpretation of high-throughput data. <i>PLoS Computational Biology</i> , 2017 , 13, e1005694	5	17
274	LetQ give BACH2 a breath of fresh air. <i>Blood</i> , 2017 , 130, 696-697	2.2	3

273	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. <i>Nature Medicine</i> , 2017 , 23, 1046-1054	50.5	102
272	Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. <i>British Journal of Haematology</i> , 2017 , 178, 936-948	4.5	28
271	Methylation patterns in marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017 , 30, 24-31	4.2	5
270	The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. <i>Oncotarget</i> , 2017 , 8, 7598-7613	3.3	66
269	ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration. <i>Oncotarget</i> , 2017 , 8, 85068-85084	3.3	15
268	A Fast Prize-Collecting Steiner Forest Algorithm for Functional Analyses in Biological Networks. <i>Lecture Notes in Computer Science</i> , 2017 , 263-276	0.9	2
267	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016 , 128, 1362-73	2.2	88
266	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. <i>Blood</i> , 2016 , 127, 221-32	2.2	65
265	Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines. <i>Methods in Molecular Biology</i> , 2016 , 1436, 305-12	1.4	
264	Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. <i>Leukemia</i> , 2016 , 30, 1805-15	10.7	20
263	Bayesian network data imputation with application to survival tree analysis. <i>Computational Statistics and Data Analysis</i> , 2016 , 93, 373-387	1.6	9
262	Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. <i>Annals of Oncology</i> , 2016 , 27, 1123-1128	10.3	19
261	ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1755-1755	2.2	1
260	TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL. <i>Blood</i> , 2016 , 128, 4035-4035	2.2	1
259	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , 2016 , 128, 4096-4096	2.2	1
258	The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents. <i>Blood</i> , 2016 , 128, 4185-4185	2.2	2
257	Targeting the Epigenome and the Cell Signaling As Novel Therapeutic Approaches for Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2016 , 128, 4186-4186	2.2	2
256	Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529. <i>Blood</i> , 2016 , 128, 4187-4187	2.2	3

255	Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. <i>Oncotarget</i> , 2016 , 7, 58142-58147	3.3	21
254	Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. <i>Oncotarget</i> , 2016 , 7, 79637-79653	3.3	18
253	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. <i>Oncotarget</i> , 2016 , 7, 84675-84687	3.3	31
252	The genetic landscape of dural marginal zone lymphomas. <i>Oncotarget</i> , 2016 , 7, 43052-43061	3.3	16
251	Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 4367-4367	2.2	
250	Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax. <i>Blood</i> , 2016 , 128, 3017-3017	2.2	
249	Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2016 , 128, 4099-4099	2.2	
248	Staining the target: CD37 expression in lymphomas. <i>Blood</i> , 2016 , 128, 3022-3023	2.2	12
247	Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. <i>Nature Communications</i> , 2016 , 7, 13719	17.4	28
246	The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. <i>Blood</i> , 2016 , 127, 2082-92	2.2	150
245	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. <i>Clinical Cancer Research</i> , 2015 , 21, 1628-38	12.9	188
244	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015 , 27, 744	24.3	2
243	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. <i>Leukemia</i> , 2015 , 29, 1390-401	10.7	32
242	Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. <i>Cancer Cell</i> , 2015 , 27, 516-32	24.3	283
241	Histologic transformation in marginal zone lymphomas. <i>Annals of Oncology</i> , 2015 , 26, 2329-35	10.3	61
240	Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma. <i>OncImmunology</i> , 2015 , 4, e1030560	7.2	17
239	Life expectancy of young adults with follicular lymphoma. <i>Annals of Oncology</i> , 2015 , 26, 2317-22	10.3	27
238	Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. <i>Cell Reports</i> , 2015 , 11, 564-76	10.6	41

237	The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015 , 29, 503-7	10.7	62
236	Two types of BCR interactions are positively selected during leukemia development in the E μ CL1 transgenic mouse model of CLL. <i>Blood</i> , 2015 , 125, 1578-88	2.2	35
235	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015 , 125, 1922-31	2.2	40
234	The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models. <i>British Journal of Haematology</i> , 2015 , 171, 378-86	4.5	4
233	Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. <i>Oncotarget</i> , 2015 , 6, 3394-408	3.3	50
232	PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1223-8	1.9	37
231	Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. <i>British Journal of Haematology</i> , 2015 , 168, 771-83	4.5	31
230	The transcription factor ETS1 in lymphomas: friend or foe?. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1975-80	1.9	9
229	Genetic lesions in diffuse large B-cell lymphomas. <i>Annals of Oncology</i> , 2015 , 26, 1069-1080	10.3	52
228	Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor 2015 ,		3
227	Abstract 2676: The MEK-inhibitor pimasertib is synergistic with PI3K-delta and BTK inhibitors in lymphoma models 2015 ,		2
226	Abstract 3530: Gene expression profile of OTX015, a BET bromodomain inhibitor, in preclinical models of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) models 2015 ,		3
225	The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas. <i>Blood</i> , 2015 , 126, 4005-4005	2.2	1
224	Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response. <i>Oncotarget</i> , 2015 , 6, 5059-71	3.3	22
223	Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. <i>Oncotarget</i> , 2015 , 6, 5735-48	3.3	12
222	Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. <i>Oncotarget</i> , 2015 , 6, 37229-40	3.3	17
221	Abstract 3526: OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents 2015 ,		2
220	The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2015 , 126, 5119-5119	2.2	

219	Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , 2014 , 164, 896-9	4.5	
218	Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , 2014 , 20, 5113-23	12.9	52
217	Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. <i>Leukemia</i> , 2014 , 28, 1334-40	10.7	90
216	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , 2014 , 123, 1681-90	2.2	87
215	MYC network mutations in high-risk chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2014 , 32, 155-7	1.3	1
214	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 264-73	5	9
213	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. <i>Seminars in Cancer Biology</i> , 2014 , 24, 33-42	12.7	57
212	The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma. <i>Blood</i> , 2014 , 124, 3113-3113	2.2	1
211	BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrnas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014 , 124, 4495-4495	2.2	1
210	The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. <i>Blood</i> , 2014 , 124, 705-705	2.2	7
209	The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response. <i>Blood</i> , 2014 , 124, 1782-1782	2.2	1
208	Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts. <i>Blood</i> , 2014 , 124, 1679-1679	2.2	
207	Convergent Mutations and New Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2014 , 124, 781-781	2.2	
206	The management of nongastric MALT lymphomas. <i>Oncology</i> , 2014 , 28, 86-93	1.8	12
205	Risk factors of central nervous system relapse in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1908-14	1.9	27
204	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. <i>Blood</i> , 2013 , 122, 2683-93	2.2	75
203	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. <i>Annals of Oncology</i> , 2013 , 24, 1378-84	10.3	13
202	Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013 , 163, 194-204	4.5	16

201	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013 , 122, 2673-82	2.2	154
200	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 1403-12	2.2	357
199	Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. <i>British Journal of Haematology</i> , 2013 , 160, 47-52	4.5	59
198	Genome-wide DNA profiling of HIV-related B-cell lymphomas. <i>Methods in Molecular Biology</i> , 2013 , 973, 213-26	1.4	
197	The changing paradigm of chronic lymphocytic leukemia management. <i>European Journal of Internal Medicine</i> , 2013 , 24, 401-10	3.9	7
196	Pathologic diagnosis: molecular genetics 2013 , 56-81		
195	MALT lymphoma: extranodal marginal zone B-cell lymphoma of MALT 2013 , 250-262		
194	MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1087-90	1.9	57
193	Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. <i>Current Opinion in Hematology</i> , 2013 , 20, 374-81	3.3	15
192	Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis. <i>British Journal of Haematology</i> , 2013 , 160, 719-22	4.5	5
191	Genome-wide high resolution DNA profiling of hairy cell leukaemia. <i>British Journal of Haematology</i> , 2013 , 162, 566-9	4.5	17
190	Prognostic impact of monocyte count at presentation in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2013 , 162, 465-73	4.5	36
189	Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013 , 122, 2233-41	2.2	33
188	Abstract A219: OTX015, a bromodomain and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma. 2013 ,		3
187	Abstract 3853: Humanized NOD/Scid/IL2g ^{-/-} tumor grafts recapitulate primary anaplastic large cell lymphoma. 2013 ,		2
186	Discovering subgroups of patients from DNA copy number data using NMF on compacted matrices. <i>PLoS ONE</i> , 2013 , 8, e79720	3.7	6
185	Where Do We Stand in the Genomics of Lymphomas? 2013 , 495-541		
184	MALT Lymphoma (Extranodal Marginal Zone B-Cell Lymphoma) 2013 , 111-126		

183	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. <i>Blood</i> , 2013 , 122, 77-77	2.2	
182	Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells. <i>Cancer Science</i> , 2012 , 103, 1397-404	6.9	7
181	Absence of NOTCH1 gene mutations in MALT lymphomas. <i>British Journal of Haematology</i> , 2012 , 157, 382-4	4.5	9
180	Incidence, risk factors and outcome of histological transformation in follicular lymphoma. <i>British Journal of Haematology</i> , 2012 , 157, 188-96	4.5	75
179	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2012 , 10, 18	8.5	18
178	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 119, 2854-62	2.2	236
177	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. <i>Blood</i> , 2012 , 120, 1274-81	2.2	80
176	MYD88 somatic mutations in MALT lymphomas. <i>British Journal of Haematology</i> , 2012 , 158, 662-4	4.5	35
175	Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2988-94	2.2	125
174	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , 2012 , 209, 1537-51	16.6	289
173	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. <i>Haematologica</i> , 2012 , 97, 849-53	6.6	9
172	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , 2012 , 30, 46-9	1.3	18
171	Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. <i>International Journal of Cancer</i> , 2012 , 130, 3006-10	7.5	24
170	Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. <i>British Journal of Haematology</i> , 2012 , 156, 354-7	4.5	9
169	Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012 , 53, 71-6	1.9	9
168	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , 2012 , 23, 729-735	10.3	17
167	An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 792-800	3.5	18
166	A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. <i>Haematologica</i> , 2012 , 97, 1085-91	6.6	85

165	The Brd-Inhibitor OTX015 Is Active in Pre-Clinical Models of Mature B-Cell Lymphoid Tumors. <i>Blood</i> , 2012 , 120, 1657-1657	2.2	3
164	The Brd-Inhibitor OTX015 Shows Pre-Clinical Activity in Anaplastic Large T-Cell Lymphoma (ALCL). <i>Blood</i> , 2012 , 120, 4872-4872	2.2	2
163	Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 712-712	2.2	
162	Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. <i>Journal of Experimental Medicine</i> , 2011 , 208, 1389-401	16.6	483
161	Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. <i>Blood</i> , 2011 , 118, 6904-8	2.2	298
160	Alteration of BIRC3 and multiple other NF- κ B pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , 2011 , 118, 4930-4	2.2	151
159	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011 , 117, 1595-604	2.2	145
158	Genomic profiles of MALT lymphomas: variability across anatomical sites. <i>Haematologica</i> , 2011 , 96, 1064-666		36
157	B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. <i>British Journal of Haematology</i> , 2011 , 153, 3-14	4.5	21
156	Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2011 , 152, 777-80	4.5	14
155	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011 , 153, 499-503	4.5	11
154	Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2011 , 155, 274-7	4.5	42
153	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011 , 154, 590-9	4.5	35
152	Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2011 , 35, 1419-22	2.7	4
151	Biased immunoglobulin genes rearrangement in mantle cell lymphoma: Hints to identify the normal B-cell counterpart. <i>Clinical Oncology and Cancer Research</i> , 2011 , 8, 65-70		
150	13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 633-43	5	57
149	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011 , 29, 38-41	1.3	23
148	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2011 , 29, 91-9	1.3	24

147	In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. <i>Hematological Oncology</i> , 2011 , 29, 164-6	1.3	3
146	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , 2011 , 117, 3391-401	2.2	249
145	Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. <i>Leukemia Research</i> , 2011 , 35, 808-13.7	4	
144	Anaplastic lymphoma kinase in human cancer. <i>Journal of Molecular Endocrinology</i> , 2011 , 47, R11-23	4.5	96
143	Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas. <i>Modern Pathology</i> , 2011 , 24, 126-37	9.8	20
142	The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years. <i>Blood</i> , 2011 , 118, 1593-1593	2.2	4
141	BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL). <i>Blood</i> , 2011 , 118, 2634-2634		
140	Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers. <i>Blood</i> , 2011 , 118, 2660-2660	2.2	
139	Recurrent 11q24.3 Gain Contributes to the Pathogenesis of Diffuse Large B Cell Lymphoma (DLBCL) by Dereglulating ETS1 and FLI1. <i>Blood</i> , 2011 , 118, 1386-1386	2.2	
138	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , 2011 , 118, 263-263		
137	Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway. <i>Blood</i> , 2011 , 118, 1359-1359	2.2	
136	MALT lymphomas: pathogenesis can drive treatment. <i>Oncology</i> , 2011 , 25, 1134-42, 1147	1.8	35
135	Genome wide DNA-profiling of HIV-related B-cell lymphomas. <i>British Journal of Haematology</i> , 2010 , 148, 245-55	4.5	56
134	IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010 , 149, 299-302	4.5	1
133	Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 149, 569-77	4.5	45
132	Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. <i>British Journal of Haematology</i> , 2010 , 150, 229-32	4.5	2
131	Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. <i>British Journal of Haematology</i> , 2010 , 151, 221-31	4.5	45
130	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010 , 151, 435-9	4.5	15

129	Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. <i>Clinical Cancer Research</i> , 2010 , 16, 620-8	12.9	38
128	Serotonin receptor 3A expression in normal and neoplastic B cells. <i>Pathobiology</i> , 2010 , 77, 129-35	3.6	22
127	Treatment of gastric marginal zone lymphoma of MALT type. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2141-52	4	14
126	Patterns of survival of follicular lymphomas at a single institution through three decades. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1028-34	1.9	29
125	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010 , 95, 1792-6	6.6	74
124	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , 2010 , 51, 822-38	1.9	8
123	An integrated Bayesian analysis of LOH and copy number data. <i>BMC Bioinformatics</i> , 2010 , 11, 321	3.6	8
122	The clinical and biological features of a series of immunophenotypic variant of B-CLL. <i>European Journal of Haematology</i> , 2010 , 85, 120-9	3.8	11
121	Genomic profiling of Richter syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , 2010 , 28, 62-7	1.3	34
120	Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. <i>International Journal of Cancer</i> , 2010 , 127, 2300-12	7.5	58
119	Syk expression patterns differ among B-cell lymphomas. <i>Leukemia Research</i> , 2010 , 34, e243-5	2.7	2
118	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , 2010 , 116, 1371-1371	2.2	1
117	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , 2010 , 116, 3611-3611	2.2	1
116	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 3578-3578	2.2	
115	Molecular History of Richter Syndrome: Origin From a Common Ancestor Cell Already Present at Chronic Lymphocytic Leukemia Diagnosis. <i>Blood</i> , 2010 , 116, 2425-2425	2.2	1
114	The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. <i>Blood</i> , 2010 , 116, 3601-3601	2.2	
113	Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL). <i>Blood</i> , 2010 , 116, 1369-1369	2.2	
112	IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. <i>Blood</i> , 2010 , 116, 2951-2951	2.2	

111	Long-term outcome following <i>Helicobacter pylori</i> eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. <i>Annals of Oncology</i> , 2009 , 20, 1086-93	10.3	96
110	Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. <i>Clinical Cancer Research</i> , 2009 , 15, 4415-22	12.9	155
109	Bayesian DNA copy number analysis. <i>BMC Bioinformatics</i> , 2009 , 10, 10	3.6	33
108	A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. <i>Hematological Oncology</i> , 2009 , 27, 154-9	1.3	10
107	A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. <i>Genes Chromosomes and Cancer</i> , 2009 , 48, 603-14	5	113
106	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009 , 144, 492-506	4.5	100
105	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. <i>British Journal of Haematology</i> , 2009 , 146, 64-75	4.5	120
104	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. <i>Leukemia</i> , 2009 , 23, 1118-26	10.7	87
103	Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. <i>Nature</i> , 2009 , 459, 717-21	50.4	826
102	BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. <i>Human Pathology</i> , 2009 , 40, 645-52	3.7	87
101	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. <i>Journal of Translational Medicine</i> , 2009 , 7, 76	8.5	31
100	The NF- κ B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. <i>Blood</i> , 2009 , 113, 4918-21	2.2	205
99	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. <i>Blood</i> , 2009 , 114, 4696-702	2.2	95
98	Bayesian Joint Estimation of CN and LOH Aberrations. <i>Lecture Notes in Computer Science</i> , 2009 , 1109-1117		
97	High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. <i>British Journal of Haematology</i> , 2008 , 141, 622-30	4.5	31
96	Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. <i>British Journal of Haematology</i> , 2008 , 143, 532-6	4.5	53
95	Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. <i>Human Pathology</i> , 2008 , 39, 1483-94	3.7	29
94	Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2008 , 44, 1829-34	7.5	26

93	Marginal zone lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2008 , 22, 883-901, viii	3.1	40
92	Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. <i>Annals of Oncology</i> , 2008 , 19, 835-46	10.3	71
91	The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion, and lineage commitment of primed human CD4+IL-7Rhi T cells. <i>European Journal of Immunology</i> , 2008 , 38, 30-9	6.1	33
90	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. <i>Leukemia Research</i> , 2008 , 32, 1628-32	2.7	1
89	Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008 , 112, 801-801	2.2	3
88	The Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21. <i>Blood</i> , 2008 , 112, 480-480	2.2	
87	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008 , 112, 478-478	2.2	
86	Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Blood</i> , 2008 , 112, 778-778	2.2	
85	Bendamustine in lymphomas: more to combine?. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1264-6	1.9	2
84	Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. <i>Haematologica</i> , 2007 , 92, 56-65	6.6	33
83	Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type. <i>Hematological Oncology</i> , 2007 , 25, 184-8	1.3	7
82	Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. <i>Genes Chromosomes and Cancer</i> , 2007 , 46, 226-38	5	57
81	Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2007 , 46, 1109-18	5	18
80	Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. <i>British Journal of Haematology</i> , 2007 , 138, 316-23	4.5	53
79	Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 410-2	1.9	91
78	A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals. <i>Pathobiology</i> , 2007 , 74, 264-9	3.6	3
77	Oncogenic BARD1 isoforms expressed in gynecological cancers. <i>Cancer Research</i> , 2007 , 67, 11876-85	10.1	50
76	The cellular origin of mantle cell lymphoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2007 , 39, 1747-53	5.6	57

75	Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. <i>Human Pathology</i> , 2007 , 38, 787-92	3.7	28
74	Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients. <i>Leukemia and Lymphoma</i> , 2007 , 48, 104-8	1.9	37
73	Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2007 , 48, 158-67	1.9	16
72	Long Term Outcome of Gastric MALT Lymphoma Patients Treated with Anti-Helicobacter (Antibiotic and Proton-Pump Inhibitor) Regimens.. <i>Blood</i> , 2007 , 110, 2583-2583	2.2	2
71	Identification of New Recurrent Lesions and Clinical Subsets by Genome-Wide DNA Profiling in Chronic Lymphocytic Leukemia with 17p Deletion.. <i>Blood</i> , 2007 , 110, 4696-4696	2.2	
70	Genome-Wide DNA Profiling Identifies a Stable Profile Although with Aberrations Targeting the Fibroblast Growth Factor Pathway in Hairy Cell Leukemia.. <i>Blood</i> , 2007 , 110, 4698-4698	2.2	
69	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. <i>Blood</i> , 2007 , 110, 3089-3089	2.2	
68	Chromosome band 6q deletion pattern in malignant lymphomas. <i>Cancer Genetics and Cytogenetics</i> , 2006 , 165, 106-13		27
67	Update on the molecular biology of mantle cell lymphoma. <i>Hematological Oncology</i> , 2006 , 24, 22-7	1.3	77
66	A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. <i>Journal of Experimental Medicine</i> , 2006 , 203, 1481-92	16.6	64
65	Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa?. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1348-9	9.7	10
64	Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer <i>Streptomyces argillaceus</i> exhibits improved transcriptional repressor activity: implications for cancer therapy. <i>Nucleic Acids Research</i> , 2006 , 34, 1721-34	20.1	73
63	Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. <i>Neoplasia</i> , 2006 , 8, 851-61	6.4	40
62	Marginal Zone B-Cell Lymphomas 2006 , 381-396		2
61	Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2006 , 132, 303-16	4.5	152
60	Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. <i>British Journal of Haematology</i> , 2006 , 134, 27-36	4.5	52
59	Delving deeper into MALT lymphoma biology. <i>Journal of Clinical Investigation</i> , 2006 , 116, 22-6	15.9	50
58	In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas.. <i>Blood</i> , 2006 , 108, 2520-2520	2.2	1

57	Hierarchy of Human B Cell Regeneration after Rituximab Therapy.. <i>Blood</i> , 2006 , 108, 936-936	2.2	
56	Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). <i>Journal of Clinical Oncology</i> , 2005 , 23, 705-11	2.2	166
55	State-of-the-art therapeutics: marginal-zone lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6415-20	2.2	92
54	Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. <i>Nature Immunology</i> , 2005 , 6, 769-76	19.1	948
53	Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2005 , 43, 1-10	5	29
52	IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. <i>Journal of Pathology</i> , 2005 , 206, 320-7	9.4	21
51	Clinical activity of rituximab in gastric marginal zone non-Hodgkin@ lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1979-83	2.2	218
50	In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. <i>Annals of Oncology</i> , 2005 , 16, 1169-76	10.3	56
49	Another Piece of the MALT Lymphomas Jigsaw. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4832-4	2.2	6
48	Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. <i>Journal of Immunology</i> , 2005 , 175, 7837-47	5.3	95
47	Inhibition of the B Cell Associated Tyrosine Kinase SYK as a Potential Therapeutic Target in Aggressive Lymphomas.. <i>Blood</i> , 2005 , 106, 1469-1469	2.2	
46	Molecular basis of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2004 , 124, 130-40	4.5	80
45	Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. <i>British Journal of Haematology</i> , 2004 , 124, 289-98	4.5	23
44	Mantle cell lymphoma. <i>Current Opinion in Hematology</i> , 2004 , 11, 411-8	3.3	26
43	Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases. <i>Thrombosis and Haemostasis</i> , 2003 , 90, 893-7	7	116
42	Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. <i>Oncogene</i> , 2003 , 22, 451-5	9.2	82
41	The class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23. <i>Leukemia</i> , 2002 , 16, 1396; author reply 1396-7	10.7	1
40	Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. <i>Blood</i> , 2002 , 99, 2541-4	2.2	91

39	Mantle cell lymphoma: new treatments targeted to the biology. <i>Clinical Lymphoma and Myeloma</i> , 2002 , 3, 90-6		5
38	Genetic alterations underlying the pathogenesis of MALT lymphoma. <i>The Hematology Journal</i> , 2002 , 3, 10-3		7
37	Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. <i>Blood</i> , 2001 , 98, 781-6	2.2	50
36	MALT lymphoma and other marginal zone lymphomas 2001 , 126-140		
35	Association of gastric and Waldeyer's ring lymphoma: a molecular study. <i>Hematological Oncology</i> , 2000 , 18, 15-9	1.3	8
34	Prognostic models for diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2000 , 18, 61-73	1.3	17
33	Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas. <i>Leukemia</i> , 2000 , 14, 446-8	10.7	21
32	BCL10 gene mutations rarely occur in lymphoid malignancies. <i>Leukemia</i> , 2000 , 14, 905-8	10.7	19
31	The gastric marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2000 , 96, 410-419	2.2	195
30	Eradication of <i>Borrelia burgdorferi</i> infection in primary marginal zone B-cell lymphoma of the skin. <i>Human Pathology</i> , 2000 , 31, 263-8	3.7	183
29	Extranodal marginal zone B-cell lymphoma genotyping by Alu-polymerase chain reaction. <i>Leukemia and Lymphoma</i> , 2000 , 38, 605-10	1.9	2
28	The gastric marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2000 , 96, 410-419	2.2	35
27	Allelic expression of p73 in human ovarian cancers. <i>Annals of Oncology</i> , 1999 , 10, 949-53	10.3	11
26	Molecular genetics of extranodal marginal zone (MALT-type) B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 1999 , 35, 57-68	1.9	16
25	Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective controlled clinical trials. <i>Leukemia and Lymphoma</i> , 1999 , 35, 139-46	1.9	12
24	Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 1999 , 36, 147-50	1.9	11
23	Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials. <i>Leukemia and Lymphoma</i> , 1999 , 35, 537-44	1.9	4
22	Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. <i>Annals of Oncology</i> , 1999 , 10, 1023-33	10.3	118

21	CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers 1999 , 26, 176-180		76
20	Clonality assessment in blood of patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 1999 , 32, 375-9	1.9	10
19	Analysis of BCL-10 gene mutations in ovarian cancer cell lines. <i>Annals of Oncology</i> , 1999 , 10, 1259	10.3	3
18	Microsatellite instability in gastric MALT lymphomas and other associated neoplasms. <i>Annals of Oncology</i> , 1999 , 10, 783-8	10.3	10
17	Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach. <i>Leukemia</i> , 1998 , 12, 247-9	10.7	17
16	Cardiac involvement in HIV-related non-Hodgkin@ lymphoma: a case report and short review of the literature. <i>Annals of Hematology</i> , 1998 , 77, 75-8	3	30
15	Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. <i>New England Journal of Medicine</i> , 1998 , 338, 804-10	59.2	196
14	Management of rare forms of lymphoma. <i>Current Opinion in Oncology</i> , 1998 , 10, 377-84	4.2	10
13	Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. <i>Annals of Oncology</i> , 1998 , 9, 779-81	10.3	60
12	Palmar-plantar erythrodysesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event?. <i>Acta Oncologica</i> , 1997 , 36, 653-4	3.2	7
11	Clinical relevance of bcl-2(MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma. <i>British Journal of Cancer</i> , 1997 , 76, 36-9	8.7	10
10	Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. <i>Leukemia and Lymphoma</i> , 1997 , 26, 527-37	1.9	145
9	Angiotropic (Intravascular) Large Cell Lymphoma: Case Report and Short Discussion of the Literature. <i>Tumori</i> , 1997 , 83, 772-775	1.7	11
8	Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. <i>Acta Haematologica</i> , 1997 , 97, 187-8	2.7	
7	Primary extranodal non-Hodgkin@ lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. <i>Annals of Oncology</i> , 1997 , 8, 727-37	10.3	261
6	Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. <i>British Journal of Haematology</i> , 1997 , 97, 830-6	4.5	36
5	Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas. <i>Annals of Oncology</i> , 1996 , 7, 1023-7	10.3	8
4	B-cell chronic lymphocytic leukemia786-792		

3 MALT and other marginal zone lymphomas104-120

2 Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer

1

1 Fast and Robust Segmentation of Copy Number Profiles Using Multi-Scale Edge Detection

1